From the Aventis Pasteur, 1541 avenue Marcel
Mérieux, 69280 Marcy l'Etoile, France, the ¶ Metalloprotein
Research Group, The Randall Center for Molecular Mechanisms of Cell
Function, King's College London, London SE1 1UL, United Kingdom,
and the
Centre for Applied Microbiology and Research,
Salisbury SP4 0JG, United Kingdom
Received for publication, May 7, 2002, and in revised form, February 4, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The transferrin receptor of Neisseria
meningitidis is composed of the transmembrane protein TbpA and
the outer membrane protein TbpB. Both receptor proteins have the
capacity to independently bind their ligand human transferrin (htf). To
elucidate the specific role of these proteins in receptor function,
isothermal titration calorimetry was used to study the interaction
between purified TbpA, TbpB or the entire receptor (TbpA + TbpB) with
holo- and apo-htf. The entire receptor was shown to contain a single
high affinity htf-binding site on TbpA and approximately two lower affinity binding sites on TbpB. The binding sites appear to be independent. Purified TbpA was shown to have strong ligand preference for apo-htf, whereas TbpA in the receptor complex with TbpB
preferentially binds the holo form of htf. The orientation of the
ligand specificity of TbpA toward holo-htf is proposed to be the
physiological function of TbpB. Furthermore, the thermodynamic mode of
htf binding by TbpB of isotypes I and II was shown to be different. A
protocol for the generation of active, histidine-tagged TbpB as well as its individual N- and C-terminal domains is presented. Both domains are
shown to strongly interact with each other, and isothermal titration
calorimetry and circular dichroism experiments provide clear evidence
for this interaction causing conformational changes. The N-terminal
domain of TbpB was shown to be the site of htf binding, whereas the
C-terminal domain is not involved in binding. Furthermore, the
interactions between TbpA and the different domains of TbpB have been demonstrated.
Meningococcal disease continues to be a worldwide health problem
and can lead to death within several hours if untreated (1). There is
currently no vaccine to prevent serogroup B meningococcal disease. The
proteins that form the transferrin receptor of Neisseria meningitidis are promising candidates for inclusion in such a vaccine (2).
The receptor consists of two types of subunits, TbpA and TbpB
(transferrin-binding proteins
A and B), both of which have the capacity to independently bind their ligand, human transferrin (htf)1 (3). TbpA (100 kDa) is
thought to be a porin-like integral membrane protein that is proposed
to serve as channel for the transport of iron across the outer
membrane. TbpA shares sequence similarities with FepA and FhuA (4).
Both proteins have been shown to form an antiparallel A sequence alignment of all currently available N. meningitidis TbpB sequences reveals the presence of two different
isotypes (12). Both isotypes differ in their molecular masses:
isotype I proteins (such as strain B16B6) have molecular masses of
~68 kDa, whereas isotype II proteins (such as strain M982) are
characterized by molecular masses of ~80-90 kDa (13). These
differences are caused by large sequence inserts predominantly in the
C-terminal part of isotype II proteins (4). TbpB sequences from other bacteria such as Neisseria gonorrhoeae (8) or
Moraxella catarrhalis (14) resemble the isotype II proteins
found in N. meningitidis, indicating that this isotype is
predominant. However, the physiological relevance for two isoforms in
the meningococcus is not understood.
The immunological properties of both proteins have been studied
extensively. Antibodies to TbpA and TbpB are detected in the sera of
infected individuals as well as of healthy carriers (2). The receptor
(TbpA + B) was shown to induce bactericidal antibodies in laboratory
animals and is protective in a mouse infection model (15). TbpB was
shown to be protective and to generate bactericidal antibodies (12,
16), whereas TbpA can confer protection in a mouse challenge model
without a detectable bactericidal antibody response (17). The two
isotypes of TbpB are also reflected in their immunogenic behavior,
because it has been demonstrated that antibodies raised against one
TbpB isotype do not have any cross-bactericidal activity toward
meningococcal strains containing a TbpB that belongs to the other
isotype (12). This finding is of importance for vaccine development
because it implies that a TbpB-based meningococcal vaccine needs to
contain at least a representative of each isotype to achieve broad
cross-protection (12).
In contrast to the detailed knowledge concerning the immunogenicity of
the receptor, a number of fundamental questions about the structure and
function of the transferrin receptor remain to be answered. First, it
is generally accepted that the receptor consists of TbpA and TbpB.
However, the architecture of the receptor is unclear and reports on the
TbpB:TbpA stoichiometry range from 1:2 (18) to 2:1 (19), 5:1 (3), and
9:1 to 15:1 (20). Second, the study of meningococcal and gonococcal
mutants lacking the gene for either TbpA or B has shown that both
proteins are required for the optimal uptake of htf iron (21, 22). In
contrast to TbpA, which forms a transmembrane pore permitting iron
internalization, the role of TbpB in iron uptake remains unclear.
Third, it needs to be elucidated whether htf binding by TbpA and TbpB
occurs in an independent or sequential fashion. Both modes of ligand
binding are supported by previous reports (3, 18), and the number of
htf-binding sites per receptor has been variously described. Fourth,
little is known about the affinities with which the iron-free and
iron-loaded forms of htf are bound by the bacterial receptor and how
these affinities compare with the human transferrin receptor. Fifth,
based on antigenic and sequence differences, TbpBs can be divided into
isotype I and II proteins (12, 13). It has not been established whether
this classification is also reflected in differential htf binding
characteristics. These questions will be addressed in the first part of
this article where the interaction of purified TbpA, TbpB, or the
receptor complex with apo- and holo-htf is analyzed by isothermal
titration calorimetry (ITC) (23).
In the second part we present a protocol for the cloning, expression,
and purification of active, recombinant TbpB as well as its individual
N- and C-terminal domains. These proteins have been used to
characterize the interaction of both domains with each other as well as
with htf and TbpA. Binding interactions were monitored by a combination
of ITC, differential scanning calorimetry (DSC), and cd. In
addition, DSC has shown utility in the characterization of vaccine antigens.
Cloning, Expression, and Purification of Recombinant
TbpA--
TbpA was obtained as reported previously (24).
Overexpression and Purification of N-terminally Lipidated TbpB
(lip-TbpB)--
Recombinant, N-terminally lipidated TbpB of strains
B16B6 (B:2a; P1.2) and M982 (B:9;P1.9) was overexpressed in
Escherichia coli as described previously (25). The protein
was purified by affinity chromatography on transferrin-Sepharose
(26).
Purification of the Transferrin Receptor (TbpA + B) from N. meningitidis--
The transferrin receptor from N. meningitidis strain M982 (isotype II) was purified as described
previously (27) with the exception that membrane proteins were
extracted from N. meningitidis by overnight incubation at
4 °C using PBS containing 2% (v/v) Elugent (Calbiochem-Novabiochem
Inc.).
Cloning, Overexpression, and Purification of Histidine-tagged
TbpB M982 (isotype II) and Its Individual Domains--
The gene
sequences coding for His6-TbpB (amino acids 2-691), N-ter
(amino acids 2-351), and C-ter (amino acids 352-691) of N. meningitidis strain M982 were cloned into the plasmid pET28a (Novagen, Madison, WI) and linearized by the restriction enzymes NdeI and BamHI (Invitrogen). In this way, the
gene sequence corresponding to a hexahistidine tag was added to the
N-terminal end of all three inserts. PCR amplification of the
corresponding DNA sequences was undertaken using pTG3721 (4) as
template. PCR amplifications were performed on a PTC-200 thermal cycler
(MJ-Research, Merck Eurolab, Fontenay-sous-Bois, France) using an
Expand Long Template PCR system (Roche Diagnostics, Meylan, France).
The experimental conditions suggested by the supplier were used. For
each of the three constructs, restriction sites for NdeI and
for BamHI were introduced into the forward and reverse
primers, respectively. Moreover, a stop codon was added into the
reverse primer for the specific amplification of the N-terminal
tbpB fragment. The following primers were used to amplify
the full-length, N-terminal, and C-terminal fragments of
tbpB: 5'-ggaattccatatgctgggcggcggcggcag-3' and
5'-cgggatccttattgcacaggctgttggcg-3',
5'-ggaattccatatgctgggcggcggcggcag-3' and
5'-cgggatccttattccagtttgtctttggttttcg-3',
5'-ggaattccatatgaatggcgcggcggcttcag-3', and
5'-cgggatccttattgcacaggctgttggcg-3', respectively.
The three PCR products were digested with NdeI and
BamHI and cloned into pET28a, and E. coli
BL21(DE3) were transformed with the ligation mixes. Plasmids from
recombinant kanamycin-resistant clones were purified, and the identity
of the ligated fragments was verified by DNA sequencing of the inserts
and flanking regions. Cultures of transformed E. coli were
grown at 37 °C on LB broth supplemented with kanamycin (25 µg/ml).
Protein expression was induced at an A600
of 0.6 by the addition of
isopropyl-
The bacterial pellet resulting from a 1-liter culture was resuspended
at room temperature in 95 ml of 50 mM Tris/HCl, 100 µM Pefablock (Interbiotech, Montluçon, France), 100 µg/ml lysozyme (Sigma-Aldrich), pH 8.0, and gently agitated for 30 min. Afterward, MgCl2 and benzonase (Merck) were added to
final concentrations of 1 mM and 1 units/ml, respectively.
The bacterial suspension was then placed on ice, and cell lysis was
achieved by ultrasound treatment (3 × 2 min) using a
Branson-Sonifer 450. The resulting solution was then centrifuged at
18,000 × g for 25 min at 5 °C. Aliquots of the
resulting supernatant and pellet were analyzed by SDS-PAGE, and
recombinant proteins were detected by Western blot analysis using an
anti-polyhistidine monoclonal antibody (Novagen).
Protein Purification from the Supernatant (His6-TbpB
and C-ter)--
NaCl and imidazole were added to the supernatant to
final concentrations of 0.5 and 10 mM, respectively. The
resulting solution was then filtered using a 0.45-µm cut-off and
loaded onto a 1-ml Hi-Trap chelating column (Amersham Biosciences)
previously equilibrated with buffer A (50 mM Tris/HCl, 0.5 M NaCl, 10 mM imidazole, pH 8.0). After washing
with 20 ml of buffer A, protein elution was achieved using buffer A
containing 500 mM imidazole. The protein was then dialyzed
against PBS and stored at Protein Purification from the Pellet (His6-TbpB,
N-ter)--
The pellet was washed with 100 ml of H2O at
room temperature. The water was decanted, and the pellet was
resuspended in 35 ml of buffer B (50 mM Tris/HCl, 0.5 M NaCl, 6 M guanidinium hydrochloride, 10 mM imidazole, pH 8.0). After filtration using a 0.45-µm
cut-off filter, the protein was loaded onto the Hi-Trap chelating
column previously equilibrated in buffer B. The column was washed with 10 ml of buffer B and afterward with 10 ml of buffer C (50 mM Tris/HCl, 0.5 M NaCl, 6 M urea,
10 mM imidazole, pH 8.0). Protein elution was achieved
using buffer C containing 500 mM imidazole. The urea
concentration in the protein preparation was then lowered by serial
dialysis against PBS containing 0.5 M arginine and 4, 2, and 0 M urea, respectively. Protein was then stored at
Isothermal Titration Calorimetry--
ITC measurements were
performed on a VP-Microcalorimeter (MicroCal, Northampton, MA). The
proteins were exhaustively dialyzed into the buffer system stated in
the legend of each figure. The ligand concentration was determined
using the Micro BCA protein reagent kit (Pierce). A typical experiment
involved a single 2-µl injection and a series of 4-µl injections
with an interval of 240 s. If not otherwise stated, the
experiments were carried out at 25 °C. The mean of the enthalpies
measured from the injection of ligand into buffer was subtracted from
raw titration data prior to curve fitting using ORIGIN software
(MicroCal). Titration curves were fitted by a nonlinear least squares
method to a function for the binding of a ligand to a macromolecule
(23). From the curve fit, the parameters Differential Scanning Calorimetry--
DSC experiments were
performed using a MicroCal VP-DSC apparatus (MicroCal). Prior to
analysis, the proteins were exhaustively dialyzed against 10 mM
Na2HPO4/NaH2PO4, 150 mM NaCl, 0.05% (v/v) Tween 20, pH 7.0, and degassed. The
dialysis buffer was used for base-line scans and was present as
reference buffer for the protein scans. The system was allowed to
equilibrate at 5 °C for 15 min, and temperatures from 5 to 100 °C
were scanned at a rate of 85 °C/h. Thermograms obtained were
analyzed using the MicroCal version of ORIGIN. The standard deviation
indicated for each parameter corresponds to the error of curve fitting.
Details concerning the calculation of thermodynamic parameters and
instrumentation can be found in Refs. 28 and 29.
Circular Dichroism--
Far-UV cd measurements were made at
25 °C using a Jasco J-810 spectropolarimeter (Tokyo, Japan) using
cuvettes with a pathlength of 0.1 mm. The proteins were exhaustively
dialyzed against 5 mM NaH2PO4/Na2HPO4, 10 mM NaCl, 0.05% (v/v) Tween 20, pH 7.0. The protein
concentrations were between 5 and 7 mg/ml. All of the protein spectra
were corrected using the spectra of the dialysis buffer.
Surface Plasmon Resonance (BIAcore) Studies--
Surface plasmon
resonance studies were carried out using the BIAcore 2000 system
(BIAcore, Uppsala, Sweden). The sensor chip CM5 and the amine coupling
kit (containing N-hydroxysuccinimide, N-ethyl-N'-[3-diethylamino-propyl]-carbodiimide,
and 1 M ethanolamine hydrochloride, pH 8.5) were also from
BIAcore. The buffer used for sample dilution and analysis was 10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA,
0.005% BIAcore surfactant, pH 7.4 (HBS buffer). TbpA was immobilized
onto activated carboxylated dextran by a covalent linkage involving the
amino groups of the protein using the protocol provided by the
manufacturer. Solutions containing 150 pmol of each ligand (diluted to
1.5 µM in HBS buffer) were passed over the sensor chip at
a flow rate of 10 µl min Study of the Interaction between TbpA, TbpB, and TbpA + B with
Apo- and Holo-transferrin
Calorimetric Titration of TbpA with Apo- and
Holo-htf--
Calorimetric titrations of TbpA with apo- and holo-htf
are shown in Fig. 1, and the derived
thermodynamic parameters are listed in Table
I. The binding of both apo-htf and
holo-htf to TbpA was driven by a large enthalpy change and opposed by
an unfavorable entropy change. The Calorimetric Titration of TbpB Isotypes I and II with
Apo- and Holo-htf--
ITC titrations of
isotype I and II TbpB with holo-htf (Fig. 2 and Table
II) show that the mode of ligand binding
is different for the two isotypes. The binding of holo-htf to isotype I
TbpB (strain B16B6) is enthalpy-driven and opposed by an unfavorable entropy change. The Calorimetric Titration of the Transferrin Receptor (TbpA + B)
Purified from N. meningitidis Strain M982 (Isotype II) with Apo- and
Holo-htf--
The entire transferrin receptor was purified from
N. meningitidis strain M982 using htf-Sepharose affinity
chromatography. The resulting protein was analyzed on a 4-20%
polyacrylamide-SDS gel (Fig.
3A) and was found to be
very pure, with the two bands identified as TbpA and TbpB.
Fig. 3B shows the calorimetric titration of the receptor
with holo-htf. In contrast to the titration of separate TbpA or TbpB, two different binding events can be distinguished. Data analysis was
carried using the experimentally determined molecular mass of
300 kDa/receptor complex (32). The data fitted very well to the two
independent binding sites model provided by the ORIGIN software and the
thermodynamic parameters obtained are listed in Table
III. A high affinity binding site
(KD = 0.71 nM) can be distinguished from
a low affinity site (KD = 22.2 nM), and
both sites appear to be independent. Most interestingly, the data show
approximately one high affinity site and approximately two low affinity
sites (Table III, n), indicating that in total three
molecules of holo-htf are needed to saturate the receptor.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-barrel (5,
6), and TbpA is thought to have a similar structure (7). TbpB (65-85
kDa) is considered to be an outer membrane protein that is anchored to
the membrane via the lipidated N-terminal part of the protein (8, 9),
and an interaction between TbpA and TbpB has been demonstrated (10,
11).
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-thiogalactopyranoside (Q-BIOgene, Illkirch,
France) to a final concentration of 1 mM. The bacteria were
harvested 1 h after protein induction by centrifugation.
45 °C.
45 °C.
H (reaction
enthalpy), KD (dissociation constant), and
n (reaction stoichiometry) can be determined directly. From
the values KD and
H, the change in
free energy (
G) and entropy change (
S) can
be calculated using the equation:
G =
RTln (1/KD) =
H
T
S, where R is the universal molar gas
constant, and T is the absolute temperature. The
thermodynamic parameters of ligand binding reported are the mean values
and standard deviations of at least two independent measurements.
1. The TbpA-ligand complex was
then washed for 6 min with HBS buffer, and the increase in resonance
units with respect to the initial base line was determined. The data
were corrected using the change in resonance units observed for the
binding of bovine serum albumin, and the reported data are the means of
three experiments. The sensor chip was regenerated by an exposure to
200 mM glycine, pH 2.0.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
H for apo-htf binding
was substantially larger than the value obtained for the binding of
holo-htf, which might indicate that the complex between apo-htf and
TbpA is maintained by more or stronger interactions as compared with
the complex between holo-htf and TbpA. This difference in
H is also reflected in differences in the binding
constants. TbpA has an affinity ~20 times greater for apo-htf than
holo-htf.
View larger version (23K):
[in a new window]
Fig. 1.
Isothermal titration calorimetry data for the
binding of human holo-htf (A) and apo-htf
(B) to TbpA of N. meningitidis strain
K454. The proteins were in 50 mM Tris/HCl, 150 mM NaCl, 0.05% (w/v) dodecylmaltoside, pH 8.0. The
corresponding parameters are shown in Table I.
Thermodynamic parameters derived from the titration of TbpA with human
holo- and apo-transferrin (see Fig. 1)
H of
14.5 kcal/mol corresponds to
an average value for a protein-protein interaction (30). In contrast to the isotype I TbpB (strain B16B6), the holo-htf binding to isotype II
TbpB (strain M982) was driven by favorable entropy and enthalpy changes. Approximately 60% of the binding energy can be attributed to
entropy changes and approximately 40% to enthalpy changes
(Table II). The observed
H of
4.0 kcal/mol
was approximately four times smaller than for the isotype I protein and
below the average for a protein-protein interaction. This difference in
H between both isotypes was also reflected in the binding
constants for holo-htf. The affinity of TbpB of B16B6 for holo-htf was
significantly higher than the M982 protein. In agreement with previous
studies (31), the interaction of both TbpB isotypes with apo-htf was
negligible. Furthermore, the number of binding sites (n)
(Table II) in all of the experiments was found to be close to 1, confirming the previously suggested 1:1 stoichiometry for the binding
of htf to TbpB (32).
View larger version (20K):
[in a new window]
Fig. 2.
Isothermal titration calorimetry data for the
binding of human holo-transferrin to lip-TbpB of N. meningitidis strain B16B6, an isotype I protein
(A), and to lip-TbpB of N. meningitidis
strain M982, an isotype II protein (B). The
proteins were in 10 mM
Na2HPO4/NaH2PO4, 0.05%
(w/v) Zwittergent 3-14, pH 7.0. The derived thermodynamic parameters
are listed in Table II.
Thermodynamic parameters derived from the titration of lip-TbpB
isotypes I and II with human holo- and apo-transferrin (see Fig. 2)
View larger version (25K):
[in a new window]
Fig. 3.
Studies of the transferrin receptor (TbpA + TbpB) purified from N. meningitidis strain M982.
A, SDS-PAGE gel of the purified receptor. The proteins were
separated on a 4-20% polyacrylamide gradient SDS gel. The molecular
mass markers on the right-hand side are annotated in kDa.
B and C, ITC data for the binding of holo-
(B) and apo-htf (C) to the purified receptor.
Ligand concentrations were very similar in both titrations.
D, repetition of the titration with apo-htf using a 3-fold
lower ligand concentration. These data were used for the determination
of the thermodynamic parameters of ligand binding. The molecular mass
of the receptor complex used for data analysis was 300 kDa as
determined previously (32). The proteins were in 10 mM
Na2HPO4/NaH2PO4, 0.05%
(w/v) Zwittergent 3-14, pH 7.0. The derived parameters can be found in
Table III.
Thermodynamic parameters derived from the titration of the transferrin
receptor (TbpA + B), isolated from N. meningitidis M982 (isotype
II), with human holo- and apo-transferrin (see Fig. 3)
Production and Characterization of Recombinant Hexahistidine-tagged TbpB (His6-TbpB, M982) and Its Individual N- and C-terminal Domains
Production of Histidine-tagged TbpB (His6-TbpB) and Its Individual N- and C-terminal Domains-- TbpB used for the above-mentioned studies corresponds to a recombinant, N-terminally lipidated form of the protein, which was purified from E. coli membranes (25, 26). This purification is rather tedious, and protein yields are relatively low. To verify whether a nonlipidated TbpB was comparable with its lipidated form, the protein was produced in fusion with a hexahistidine tag (His6-TbpB).
The sequence of the N-terminal half of TbpB can be aligned with its C-terminal half. This observation has led to the hypothesis that TbpB consists of two domains that are joined by a linker region, and it has been suggested that TbpB is a result of a gene duplication event (33-35). To characterize both domains and to study their implication in binding to htf and TbpA, the two domains were also produced as individual histidine-tagged proteins.
Following induction with
isopropyl--D-thiogalactopyranoside, a high level of
protein expression in E. coli was observed for all three
recombinant proteins. After the centrifugation of the E. coli cell lysate, the large majority of the C-ter was found to be
present in the soluble fraction, whereas the N-ter was recovered from
the insoluble fraction (Table IV).
Isolated C-ter was soluble and stable in PBS, whereas purified N-ter
was only stable in the presence of either detergent or a chaotropic
agent (Table IV). In contrast, His6-TbpB was
almost equally present in the soluble and insoluble fractions. Either
protein was purified directly from the soluble fraction
(His6-TbpB, C-ter), or protein recovered from the insoluble
fraction was denatured, purified, and then renatured
(His6-TbpB, N-ter). DSC profiles of His6-TbpB
purified from the insoluble fraction and soluble fraction are shown in Fig. 4 (A and B),
and the derived parameters are listed in Table V. Both profiles can be closely
superimposed, and the differences observed for both sets of
thermodynamic parameters are minor. This indicates that both protein
preparations are comparable and that the renaturation process of
His6-TbpB purified from the insoluble fraction is
efficient.
|
|
|
Calorimetric Titration of the N-terminal Domain of TbpB with Its
C-terminal Domain--
Fig.
5A shows a calorimetric
titration of N-ter with C-ter at 25 °C, and it is evident that both
domains strongly interact with each other. For the titration at
25 °C, a KD of 47 nM
(KA = 21.4 × 106
M1,
G =
10.0 kcal/mol)
was determined. Binding was driven by a large enthalpy change (
41.0
kcal/mol), which was compensated by an also large unfavorable entropy
change (
T
S = 31.0 kcal/mol), demonstrating a
substantial loss in the degree of conformational flexibility upon
domain interaction. Furthermore, saturation was achieved at a molar
ratio of 1:1, indicating that the recombinant domains are homogeneous
samples of correctly folded protein.
|
This titration was repeated at different temperatures, and
the enthalpy changes as a function of the temperature are shown in Fig.
5B. For these titrations, changes in free energy
(G) were found to be similar, indicating the compensation
of
H by the
T
S term. From the slope of
the line in Fig. 5B, the parameter
Cp (change of heat capacity) can be
calculated. Negative changes in
Cp can be
correlated to the burial of apolar surfaces (36). The
Cp for the interaction of both domains of
TbpB was found to be
3.16 kcal mol
1 K
1
(R2 = 0.98). This
Cp
change was significantly larger than the average value identified for a
protein-protein ligand interaction (30) (
0.2 to
0.7 kcal
mol
1 K
1). To our knowledge, such a large
value for
Cp has not been reported in the
literature and might indicate that the nature of protein-protein ligand
interaction is rather different to interdomain interactions.
Circular Dichroism Studies--
cd spectra of both individual TbpB
domains, a stoichiometric mix of both domains, and the
full-length His6-TbpB are shown in Fig.
6. The molecular ellipticity at 220 nm
can be regarded as a measure of the secondary structure content of a
protein (37). Interestingly, both the N-ter and C-ter were found to
contain very little secondary structure. Using the procedure of Taylor and Kaiser (38), a secondary structure content below 10% was estimated for both proteins, with C-ter being slightly more structured than N-ter. This is consistent with a large part of both proteins being
present in a coil conformation. However, the secondary structure content of a stoichiometric mix of both domains was found superior to
that of both domains on their own (Fig. 6). This is evidence that the
domain interaction is accompanied by structural rearrangements. The
observed conversion of disordered parts of the domains into structured
regions is likely to be related to the loss of rotational and
translational freedom expressed by the very unfavorable entropy change
(T
S = 31.0 kcal/mol; see above).
|
DSC Studies--
His6-TbpB and its individual domains
have been studied by DSC (Fig. 4 and Table V). This technique permits
the determination of the thermodynamic parameters of the thermal
unfolding, such as Tm (midpoint of protein
unfolding transition), Hcal, the enthalpy change on protein denaturation, which corresponds to the integrated peak area, and
HvH (change in van't Hoff
enthalpy), expressed by the peak width, which compared with
Hcal provides information on the content of
the cooperatively folding unit. For instance, a
HvH/
Hcal ratio of 2 is, in simple cases, an expression of two protein monomers present in
the cooperatively folding unit (for further details see Ref. 39).
The denaturation of both the N-ter and C-ter was characterized by two separate unfolding transitions (Fig. 4 and Table V). DSC profiles showing two separate unfolding transitions have been observed in the past for proteins containing two separate domains (40, 41). The C-terminal domain was found to be fairly thermostable with a Tm beyond 80 °C, which is astonishing considering the relatively low amount of secondary structure determined by cd spectroscopy (Fig. 6). N-ter was found to be much less thermostable with transitions centered around 33 and 58 °C. Both the DSC thermograms of His6-TbpB and the stoichiometric mix of N-ter with C-ter show three transitions. Furthermore, studies to evaluate the reversibility of protein unfolding have been carried out, and the obtained data are shown in Table V.
Calorimetric Titrations of His6-TbpB, N-ter, and C-ter with htf-- The presence of at least 100 mM NaCl was an absolute requirement for the solubility of His6-TbpB. However, this ionic strength leads to precipitation of the lip-TbpB (isotype II) used for the experiments presented above (Fig. 2). Therefore, experiments with the lipidated and histidine-tagged forms of TbpB had to be carried out in different buffer systems, and the data need to be compared with caution.
The calorimetric titration of
His6-TbpB with holo-htf is
shown in Fig. 7A, and the derived data are listed in Table
VI. Although holo-htf bound with an
approximately 10-fold higher affinity to His6-TbpB as
compared with lip-TbpB of isotype II (Tables II and VI), the overall
mode of htf binding to His6-TbpB and lip-TbpB was similar.
Binding was characterized by a favorable entropy change, a moderate
negative H, and a TbpB:htf stoichiometry of 1:1. This
indicates that His6-TbpB, which can be obtained more easily
and in larger amounts than the lipidated form, is suitable material for
the study of this protein.
|
|
Holo-htf bound to N-ter with a very similar affinity to His6-TbpB (Fig. 7B and Table VI). However, the enthalpy change (Table VI) for htf binding to N-ter was about three times larger than the corresponding value for the binding to His6-TbpB. No interaction between holo-htf and C-ter was observed (Fig. 7C).
Study of the Interactions between TbpA and TbpB-- Calorimetric titrations of TbpA with His6-TbpB were not successful. This failure was due to the aggregation of TbpB at concentrations above 1 mg/ml (in the buffer system used to study TbpA), which are necessary for the ligand in the ITC syringe. Therefore, surface plasmon resonance technology (BIAcore) was chosen as alternative technique to study the interaction.
An excess of TbpA was immobilized onto the BIAcore sensor chip, and 150 pmol of ligand were brought into contact with this sensor chip. The increase in resonance units was observed, and after each test the sensor chip was regenerated by a wash at low pH. Initial experiments were aimed at verifying that this washing procedure did not alter ligand binding, and very good reproducibility for a large number of consecutive cycles was noted (data not shown).
Ligands tested for interaction with TbpA included His6-TbpB, N-ter, C-ter, and a stoichiometric mix of N-ter and C-ter. In addition, heat-denatured forms of these ligands were tested. Denaturation was carried out by consecutive heating and cooling of protein in a DSC apparatus, and samples were removed when no residual enthalpy changes were noted. Controls included bovine serum albumin as well as native and denatured forms of htf and bovine transferrin.
His6-TbpB, N-ter, and C-ter were found to bind TbpA (Table VII). Denatured forms of TbpB and N-ter showed similar binding, whereas denatured C-ter did not show any binding affinity. The binding of His6-TbpB or N-ter to TbpA appeared to be independent of the ligand conformation but specific for TbpA, because denatured N-ter or His6-TbpB did not bind to control proteins such as bovine serum albumin (data not shown).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Study of the Interaction between TbpA, TbpB, and TbpA + B with Apo-
and Holo-transferrin--
ITC experiments were performed to
characterize the interaction between purified TbpA, TbpB, and TbpA + B
with iron-loaded (holo) and iron-free (apo) htf. This allowed an
assessment of the contribution of each receptor protein in htf binding.
The advantages of ITC over alternative techniques are that both ligands are unmodified and in solution and that the heat change measured is a
direct signal of a molecular interaction. ITC is the only technique
that permits the determination of the complete set of thermodynamic
parameters of ligand binding (42). Apart from the binding constant
(K), the obtained changes in enthalpy (H), and
entropy (
S) provide valuable information for the study of protein interaction. In general, negative contributions to
H can be attributed to the formation of hydrogen bonds,
van der Waals' forces, or electrostatic interaction (42). Positive
entropy changes are mainly due to the displacement of ordered water
molecules (associated with a protein) into the bulk water, whereas a
negative
S reflects a loss of conformational flexibility
as a consequence of ligand binding (for further information see Refs.
43 and 44). Furthermore, the stoichiometry of ligand binding
(n) can be determined by ITC.
Previous studies have shown that TbpB preferentially binds holo-htf, whereas TbpA does not discriminate between apo- and holo-htf (32). In this study, we have determined that TbpA has a much greater affinity for apo-htf than the holo form (Table I). This observation, in combination with the fact that in vivo the iron-free state is the predominant form of htf, indicates that in the absence of TbpB, iron acquisition from htf is slowed down by a quasi-saturation of TbpA with apo-htf. These data explain previous reports of TbpB-defective mutants of N. meningitidis, N. gonorrhoeae, Haemophilus influenzae, and M. catarrhalis, which showed either slower growth on htf-containing medium or reduced iron uptake capacity (21, 22, 45-47). The large unfavorable entropy change observed for the binding of both htf forms by TbpA is most likely to be the consequence of a loss of conformational flexibility upon htf binding, which might also be related to the conformational changes in TbpA following ligand binding as demonstrated in N. gonorrhoeae by Cornelissen et al. (48).
Cornelissen and Sparling (3) have studied htf binding to whole cells of N. gonorrhoeae using solid phase and liquid phase binding assays. They concluded that there are two independent htf-binding sites with KD values of 0.8 and 16 nM. The calorimetric titration of purified receptor with holo-htf provides evidence for there being two independent binding sites with KD values of ~0.7 and ~22 nM (Table III). Considering that the technique used by Cornelissen and Sparling is entirely different from our approach, the similarity of both sets of data is remarkable. Furthermore, these values indicate that the neisserial receptor can compete successfully with the human transferrin receptor, which was shown to bind holo-htf with affinities between 5 and 20 nM (49). However, the technique employed by Cornelissen and Sparling did not allow the attribution of obtained KD values to either TbpA or TbpB. This has been achieved by ITC. The iron-free form of htf is known to bind exclusively to TbpA but not to TbpB (32). This implies that the signal observed in the titration of the entire receptor with apo-htf corresponds to binding to TbpA. An ITC titration of the TbpA + B receptor with apo-htf at a ligand concentration similar to that used with holo-htf is shown in Fig. 3C. The same experiment with a 3-fold lower concentration of apo-htf (Fig. 3D) was used to determine the binding parameters. In both cases, there was only approximately one binding event, and the number of binding sites was found to be ~1 (n = 0.81; Table III). This n value was close to the corresponding value of the high affinity binding site seen in the titration with holo-htf (n = 0.74; Table III), which identifies the high affinity site as binding at TbpA. The fact that the low affinity binding site corresponds to binding to TbpB was also confirmed by the similarity of binding parameters of this low affinity site present in the receptor and the parameters for the titration of TbpB (isotype II) alone with holo-htf (Tables II and III).
As stated above, the experimentally determined molecular mass of 300 kDa/receptor complex (32) was used for data analysis. Under these conditions we provide evidence that the receptor has approximately one high affinity site at TbpA and approximately two low affinity sites at TbpB. This indirect information on the receptor stoichiometry needs to be validated by a direct analysis of the TbpA-TbpB stoichiometry. The receptor protein (TbpA + TbpB) analyzed in this study was purified from N. menigitidis M982 grown under iron-limiting conditions. We have studied the expression of tbpB and tbpA genes of N. menigitidis M982 grown under iron-limiting conditions using TaqMan real time quantitative reverse transcriptase-PCR and have observed a ratio of 2:1 for the expression of tbpB and tbpA genes, respectively.2 Using a similar approach, a ratio of 2:1 has been reported for the tbpB/tbpA gene expression in N. gonorrhoeae (19). The data of the tbpB/tbpA gene expression are consistent with the ITC data reported in this article.
New Insights Obtained on the Structure and Function of the Receptor-- The model of the transferrin receptor as suggested by Boulton et al. (18) contains a single htf-binding site. It was proposed that initial htf binding occurs at TbpB, which then triggers conformational changes in htf and binding by TbpA. This proposition was based on the observation by surface plasmon resonance technology that the affinities of TbpA and TbpB for htf are comparable (18). Here we show that holo-htf binding by the TbpA + B receptor occurs with an approximately 30 times higher affinity at TbpA than TbpB (Table III; KD of 0.71 nM versus 22.2 nM for binding at TbpA and TbpB, respectively), which does not suggest an initial binding event at TbpB. Our data seem to indicate that htf binds directly to the TbpA component of the receptor. In addition, we have provided evidence that there are approximately three binding sites for htf per receptor. TbpA has been identified as the high affinity site, whereas the other two binding sites represent binding at TbpB. Both binding sites appear to be independent, and no evidence for cooperative binding was obtained.
We have demonstrated that TbpA (as a component of the receptor) binds holo-htf with an ~3-fold greater affinity than apo-htf (Table III; KD of 0.71 nM versus 2.0 nM for the binding of holo- and apo-htf, respectively). In strong contrast, TbpA alone had a strong ligand preference for apo-htf (Table I; KD of 68.9 nM versus 3.7 nM for the binding of holo- and apo-htf, respectively). We now propose that within the receptor complex, TbpB shifts the ligand specificity of TbpA toward the iron-loaded form of htf. This proposition is consistent with the data from Cornelissen and Sparling (3), who demonstrated that the interaction between TbpB and TbpA in N. gonorrhoeae is accompanied by conformational changes in both proteins. We also suggest that the specific binding of holo-htf by the TbpB component of the receptor increases the local concentration of free holo-htf in the proximity of TbpA. As a consequence, this reduces apo-htf binding by TbpA, increasing the efficiency of iron uptake from htf. Thus, we propose a double function for TbpB: to shift the ligand specificity of TbpA toward holo-htf and to increase the local concentration of holo-htf in the proximity of TbpA.
Production and Characterization of Recombinant Hexahistidine-tagged
TbpB (His6-TbpB, M982) and Its Individual N- and C-terminal
Domains--
His6-TbpB, N-ter, and C-ter have been used to
determine the intramolecular architecture of TbpB. N-ter and C-ter were
shown by ITC to largely interact, with saturation at a 1:1 molar ratio and a large negative change in heat capacity
(Cp) of
3.1 kcal mol
1
K
1 (Fig. 5). The magnitude of the
Cp value suggests that extensive apolar
surface area is buried upon domain interaction. This domain interaction
is accompanied by secondary structure changes as observed by circular
dichroism spectroscopy (Fig. 6). In addition, the cd spectra of
His6-TbpB was almost superimposable upon the spectrum of
the stoichiometric mix of both domains (Fig. 6), indicating that the
observed domain interaction corresponds to the interaction of both
domains in the full-length TbpB. The role of these structural changes
in the function of TbpB remains to be elucidated.
The thermal unfolding of both the N-ter and C-ter are characterized by
two transitions (Fig. 4 and Table V), which leads to the hypothesis
that both TbpB domains contain two subdomains. This is a structural
organization also found in transferrin (50). The DSC profile of
His6-TbpB (Fig. 4A) was fairly similar to the profile of the stoichiometric mix of both domains (Fig. 4E),
confirming the cd data, which indicated a close structural resemblance
between the full-length protein and the stoichiometric mix of both
domains. The first two transitions in both profiles might be attributed to the N-terminal domain, whereas the transition centered at
approximately 80 °C corresponds to the denaturation of the
C-terminal domain. The most striking difference between the DSC
profiles of the stoichiometric mix of both domains and the profiles of
the individual domains was the up-shift of the first transition of
N-ter by approximately 11 °C accompanied by an increase in
H from 35 to 53 kcal/mol (Table V). This observed
stabilization of one subdomain of N-ter on interaction with C-ter is
thought to account for a large part of the strong exothermic signal
observed for the ITC titration of N-ter with C-ter. These data indicate
an involvement of one N-terminal subdomain in interdomain interaction.
The cd and DSC data presented do not confirm the data of vonder Haar
et al. (51), who described the N-terminal domain of N. meningitidis TbpB as highly structured and extremely stable.
However, the study of vonder Haar et al. was based on
Western blot analysis of SDS-treated protein samples, and the different
techniques employed might explain the observed discrepancies.
Information obtained from DSC can show insight into the structural arrangement of a protein but can also be used to predict long term stability of a protein. An increased Tm and an elevated degree of the reversibility of protein denaturation indicate favorable long term stability of proteins (52, 53), which is a very desirable property for any vaccine component. The thermal denaturation of C-terminal domain either as a separate protein, in complex with N-ter, or as part of the full-length protein showed a reversibility of 80-85%, which is above the average for a protein, whereas the denaturation of the N-terminal domain was much less reversible. The observed thermostability of C-ter and its high degree of reversibility predict increased long term stability of this domain. These biochemical and thermodynamic properties, together with its immunological properties (12, 34) suggest considerable potential for C-ter as a vaccine antigen.
Previous studies, mainly using solid phase htf-TbpB binding assays,
have indicated that htf-binding occurs primarily at the N-terminal
domain of TbpB (51, 54), but the participation of the C-terminal domain
in ligand binding has also been demonstrated (34, 35). We found by
isothermal calorimetric studies that C-ter did not bind htf, whereas
N-ter bound the ligand with a similar affinity as the full-length
protein (Fig. 7 and Table VI). However, the modes of htf-binding by
N-ter and His6-TbpB are very different. Htf binding by the
N-ter was enthalpy-driven, with an H largely superior to
the full-length protein, and counterbalanced by an unfavorable entropy
change. In contrast, htf binding of full-length TbpB was dominated by a
relatively large and favorable entropy change, which compensates for
the low enthalpy change. As mentioned above, enthalpy changes are often
related to the creation of molecular interactions, and one might
hypothesize that there is an optimal structural fit between N-ter and
htf (large
H), resulting in a loss of conformational
flexibility (unfavorable entropy change). For the interaction of the
full-length TbpB with htf, this optimal fit might not be achieved
(maybe because of a steric hindrance caused by the presence of C-ter),
and consequently a reduced enthalpy change and a favorable entropy
change is observed. Interestingly, the apparent stoichiometry between
N-ter:htf was found to be 2:1, whereas a 1:1 stoichiometry was observed
for the experiment with the full-length protein (Fig. 7 and Table VI).
This is consistent with a dimer of N-ter binding one molecule of htf.
As stated above, N-ter and C-ter share sequence homologies that might
be reflected in a similar structure, and N-ter dimerization might occur
in a similar fashion as N-ter/C-ter association. Further evidence for
N-ter dimerization was obtained by the DSC analysis, where for both
unfolding events of the N-ter a
HvH/
Hcal ratio of
approximately 2 was observed (Table V). Such a ratio is observed when
the cooperatively folding unit contains a homo-dimer (55).
Biochemical evidence for a conserved interaction between TbpA with TbpB has been obtained by Fuller et al. (10). We have confirmed the existence of this interaction using surface plasmon resonance technology (Table VII). Furthermore, we show that both recombinant domains of TbpB are able to bind to TbpA. The binding of N-ter to TbpA was independent of its conformation because native and denatured forms bound to TbpA. In contrast, only native C-ter but not its denatured form bound to TbpA, indicating that this interaction is conformation-specific.
New Insights Obtained on the Structure and Function of the
Receptor--
The data presented confirm that TbpB contains two
domains that can be obtained as individual, active, recombinant
proteins. The two domains were shown to strongly interact with each
other. This interaction is accompanied by an increase in secondary
structure. Surface plasmon resonance data indicate that both TbpB
domains interact with TbpA, but only the N-terminal domain of TbpB is involved in htf binding. DSC data suggest that both domains contain two
subdomains, a structural organization also found in htf.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank John Brandts for critical reading of this manuscript and the entire MicroCal team for help and support. We thank Françoise Guinet for providing samples of TbpB; Bachra Rokbi, Catherine Hessler and Monique Dupuy for helpful discussions; and David Poncet, Frédéric Greco, Mary Matheson, and Meg Sims for technical assistance.
![]() |
FOOTNOTES |
---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 33-4-37-37-90-12; Fax: 33-4-37-37-31-80; E-mail: tino.krell@aventis.com.
Published, JBC Papers in Press, February 5, 2003, DOI 10.1074/jbc.M204461200
2 G. Renauld-Mongénie and D. Poncet, unpublished data.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: htf, human transferrin; C-ter, histidine-tagged C-terminal domain of transferrin-binding protein B strain M982; DSC, differential scanning calorimetry; His6-TbpB, histidine-tagged TbpB strain M982; ITC, isothermal titration calorimetry; lip-TbpB, N-terminally lipidated TbpB; N-ter, histidine-tagged N-terminal domain of transferrin-binding protein B strain M982; PBS, phosphate-buffered saline.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Begg, N., Cartwright, K. A. V., Cohen, J., Kaczmarski, E. B., Innes, J. A., Leen, C. L. S., Nathwani, D., Singer, M., Southgate, L., Todd, W. T. A., Welsby, P. D., and Wood, M. J. (1999) J. Infect. 39, 1-15[Medline] [Order article via Infotrieve] |
2. | Gorringe, A. R., Borrow, R., Fox, A. J., and Robinson, A. (1995) Vaccine 13, 1207-1212[CrossRef][Medline] [Order article via Infotrieve] |
3. | Cornelissen, C. N., and Sparling, P. F. (1996) J. Bacteriol. 178, 1437-1444[Abstract] |
4. | Legrain, M., Mazarin, V., Irwin, S. W., Bouchon, B., Quentin-Millet, M.-J., Jacobs, E., and Schryvers, A. B. (1993) Gene (Amst.) 130, 73-80[CrossRef][Medline] [Order article via Infotrieve] |
5. | Buchanan, S. K., Smith, B. S., Venkatramani, L., Xia, D., Esser, L., Palnitkar, M., Chakraborty, R., van der Helm, D., and Deisenhofer, J. (1999) Nat. Struct. Biol. 6, 56-63[CrossRef][Medline] [Order article via Infotrieve] |
6. | Locher, K. P., Rees, B., Koebnik, R., Mitschler, L., Moulinier, A., Rosenbusch, J. P., and Moras, D. (1998) Cell 95, 771-778[Medline] [Order article via Infotrieve] |
7. | Schryvers, A. B., and Stojiljkovic, I. (1999) Mol. Microbiol. 32, 1117-1123[CrossRef][Medline] [Order article via Infotrieve] |
8. | Cornelissen, C. N., and Sparling, P. F. (1994) Mol. Microbiol. 14, 843-850[Medline] [Order article via Infotrieve] |
9. | Gray-Owen, S. D., and Schryvers, A. B. (1996) Trends Microbiol. 4, 185-191[CrossRef][Medline] [Order article via Infotrieve] |
10. | Fuller, C. A., Yu, R., Irwin, S. W., and Schryvers, A. B. (1998) Microb. Pathog. 24, 75-87[CrossRef][Medline] [Order article via Infotrieve] |
11. | Boulton, I. C., Gorringe, A. R., Carr, R. J., Gorinsky, B., Joannou, C. L., and Evans, R. W. (1997) FEBS Lett. 414, 409-413[CrossRef][Medline] [Order article via Infotrieve] |
12. |
Rokbi, B.,
Renauld-Mongenie, G.,
Mignon, M.,
Danve, B.,
Poncet, D.,
Chabanel, C.,
Caugant, D. A.,
and Quentin-Millet, M.-J.
(2000)
Infect. Immun.
68,
4938-4947 |
13. | Rokbi, B., Mazarin, V., Maitre-Wilmotte, G., and Quentin-Millet, M.-J. (1993) FEMS Microbiol. Lett. 110, 51-58[CrossRef][Medline] [Order article via Infotrieve] |
14. |
Myers, L. E.,
Yang, Y.-P.,
Du, R.-P.,
Wang, Q.,
Harkness, R. E.,
Schryvers, A. B.,
Klein, M. H.,
and Loosmore, S. M.
(1998)
Infect. Immun.
66,
4183-4192 |
15. | Danve, B., Lissolo, L., Mignon, M., Dumas, P., Colombani, S., Schryvers, A. B., and Quentin-Millet, M.-J. (1993) Vaccine 11, 1214-1220[CrossRef][Medline] [Order article via Infotrieve] |
16. | Lissolo, L., Maitre-Wilmotte, G., Dumas, P., Mignon, M., Danve, B., and Quentin-Millet, M.-J. (1995) Infect. Immun. 63, 884-890[Abstract] |
17. |
West, D.,
Reddin, K.,
Matheson, M.,
Heath, R.,
Funnell, S.,
Hudson, M.,
Robinson, A.,
and Gorringe, A.
(2001)
Infect. Immun.
69,
1561-1567 |
18. | Boulton, I. C., Gorringe, A. R., Shergill, J. K., Joannou, C. L., and Evans, R. W. (1999) J. Theor. Biol. 198, 497-505[CrossRef][Medline] [Order article via Infotrieve] |
19. |
Ronpirin, C.,
Jerse, A. E.,
and Cornelissen, C. N.
(2001)
Infect. Immun.
69,
6336-6347 |
20. | Powell, N. B. L., Bishop, K., Palmer, H. M., Ala'Aldeen, D. A., Gorringe, A. R., and Borriello, S. P. (1998) J. Med. Microbiol. 47, 257-364[Abstract] |
21. | Irwin, S. W., Averil, N., Cheng, C. Y., and Schryvers, A. B. (1993) Mol. Microbiol. 8, 1125-1133[Medline] [Order article via Infotrieve] |
22. | Anderson, J. E., Sparling, P. F., and Cornelissen, C. N. (1994) J. Bacteriol. 176, 3162-3170[Abstract] |
23. | Wiseman, T., Williston, S., Brandts, J. F., and Lin, L. N. (1989) Anal. Biochem. 179, 131-137[Medline] [Order article via Infotrieve] |
24. | Oakhill, J. S., Joannou, C. L., Buchanan, S. K., Gorringe, A. R., and Evans, R. W. (2002) Biochem. J. 364, 613-616[CrossRef][Medline] [Order article via Infotrieve] |
25. | Legrain, M., Speck, D., and Jacobs, E. (1995) Protein Expression Purif. 6, 570-578[CrossRef][Medline] [Order article via Infotrieve] |
26. | Krell, T., Chevalier, M., and Lissolo, L. (2002) Protein Expression Purif. 24, 323-328[CrossRef][Medline] [Order article via Infotrieve], Greenwich, CT |
27. | Ala'Aldeen, D. A. A., Stevenson, P., Griffiths, E., Gorringe, A. R., Irons, L. I., Robinson, A., Hyde, S., and Borriello, S. P. (1994) Infect. Immun. 62, 2984-2990[Abstract] |
28. | Cooper, A. (1999) Proteins: A Comprehensive Treatise , Vol. 2 , pp. 217-270, Jai Press Inc., Greenwich, CT |
29. | Plotnikov, V. V., Brandts, J. M., Lin, L.-N., and Brandts, J. F. (1997) Anal. Biochem. 250, 237-244[CrossRef][Medline] [Order article via Infotrieve] |
30. | Stites, W. E. (1997) Chem. Rev. 97, 1233-1250[CrossRef][Medline] [Order article via Infotrieve] |
31. | Renauld-Mongénie, G., Latour, M., Poncet, D., Naville, S., and Quentin-Millet, M.-J. (1998) FEMS Microbiol. Lett. 169, 171-177[CrossRef][Medline] [Order article via Infotrieve] |
32. | Boulton, I. C., Gorringe, A. R., Allison, N., Robinson, A., Gorinsky, B., Joannou, C. L., and Evans, R. W. (1998) Biochem. J. 334, 269-273[Medline] [Order article via Infotrieve] |
33. | Mazarin, V., Rokbi, B., and Quentin-Millet, M.-J. (1995) Gene (Amst.) 158, 145-146[CrossRef][Medline] [Order article via Infotrieve] |
34. | Renauld-Mongenie, G., Poncet, D., von Olleschik-Elbheim, L., Cournez, T., Mignon, M., Schmidt, M. A., and Quentin-Millet, M.-J. (1997) J. Bacteriol. 179, 6400-6407[Abstract] |
35. | Retzer, M. D., Yu, R., and Schryvers, A. B. (1999) Mol. Microbiol. 32, 111-121[CrossRef][Medline] [Order article via Infotrieve] |
36. | Xie, D., and Freire, E. (1994) Proteins 19, 291-301[Medline] [Order article via Infotrieve] |
37. | Kelly, S. M., and Price, N. C. (1997) Biochim. Biophys. Acta 1338, 161-185[Medline] [Order article via Infotrieve] |
38. | Taylor, J. W., and Kaiser, E. T. (1987) Methods Enzymol. 154, 473-498[Medline] [Order article via Infotrieve] |
39. | Freire, E. (1995) in Methods in Molecular Biology: Protein Stability and Folding: Theory and Practice (Shirley, B. A., ed) , pp. 191-218, Humana Press Inc., Totowa, NJ |
40. |
Meijberg, W.,
Schuurman-Wolters, G. K.,
Boer, H.,
Scheek, R. M.,
and Robillard, G. T.
(1998)
J. Biol. Chem.
273,
20785-20794 |
41. | den Blaauwen, T., Fekkes, P., de Wit, J. G., Kuiper, W., and Driessen, A. J. M. (1996) Biochemistry 35, 11994-12004[CrossRef][Medline] [Order article via Infotrieve] |
42. | Holdgate, G. A. (2001) BioTechniques 31, 164-184[Medline] [Order article via Infotrieve] |
43. | Murphy, K. P., Xie, D., Garcia, K. C., Amzel, L. M., and Freire, E. (1993) Proteins 15, 113-120[Medline] [Order article via Infotrieve] |
44. | Murphy, K. P., Xie, D., Thompson, K. S., Amzel, L. M., and Freire, E. (1994) Proteins 18, 63-67[Medline] [Order article via Infotrieve] |
45. | Pintor, M., Gomez, J. A., Ferron, L., Ferreiros, C. M., and Criado, M. T. (1998) J. Med. Microbiol. 47, 757-760[Abstract] |
46. | Gray-Owen, S. D., Loosmore, S., and Schryvers, A. B. (1995) Infect. Immun. 63, 1201-1210[Abstract] |
47. |
Luke, N. R.,
and Campagnari, A. A.
(1999)
Infect. Immun.
67,
5815-5819 |
48. | Cornelissen, C. N., Anderson, J. E., and Sparling, P. F. (1997) Mol. Microbiol. 26, 25-35[CrossRef][Medline] [Order article via Infotrieve] |
49. | Ward, J. H. (1987) Invest. Radiol. 22, 74-83[Medline] [Order article via Infotrieve] |
50. | Hall, D. R., Hadden, J. M., Leonard, G. A., Bailey, S., Neu, M., Winn, M., and Lindley, P. F. (2002) Acta Crystallogr. Sect. D Biol. Crystallogr. 58, 70-80[CrossRef][Medline] [Order article via Infotrieve] |
51. | vonder Haar, R. A., Legrain, M., Kolbe, H. V. J., and Jacobs, E. (1994) J. Bacteriol. 176, 6207-6213[Abstract] |
52. | Remmele, R. L., Jr., Bhat, S. D., Phan, D. H., and Gomboltz, W. R. (1999) Biochemistry 38, 5241-5247[CrossRef][Medline] [Order article via Infotrieve] |
53. | Chang, B. S., Randall, C. S., and Lee, Y. S. (1993) Pharm. Res. (N. Y.) 10, 1478-1483 |
54. | Cornelissen, C. N., Anderson, J. E., and Sparling, P. F. (1997) Infect. Immun. 65, 822-828[Abstract] |
55. | Jelesarov, I., and Bosshardt, H. R. (1999) J. Mol. Recognit. 12, 3-18[CrossRef][Medline] [Order article via Infotrieve] |